Literature DB >> 30901077

Speaking genomics to parents offered germline testing for cancer predisposition: Use of a 2-visit consent model.

Liza-Marie Johnson1, April D Sykes2, Zhaohua Lu2, Jessica M Valdez3, Jami Gattuso4, Elsie Gerhardt5, Kayla V Hamilton5, Lynn W Harrison5, Stacy J Hines-Dowell5, Niki Jurbergs6, Rose B McGee5, Regina Nuccio5, Annastasia A Ouma5, Michele Pritchard4, Emily A Quinn7, Justin N Baker1, Belinda N Mandrell4, Kim E Nichols5.   

Abstract

BACKGROUND: Patients with cancer are increasingly offered genomic sequencing, including germline testing for cancer predisposition or other disorders. Such testing is unfamiliar to patients and families, and clear communication is needed to introduce genomic concepts and convey risk and benefit information.
METHODS: Parents of children with cancer were offered the opportunity to have their children's tumor and germline examined with clinical genomic sequencing. Families were introduced to the study with a 2-visit informed consent model. Baseline genetic knowledge and self-reported literacy/numeracy were collected before a study introduction visit, during which basic concepts related to genomic sequencing were discussed. Information was reinforced during a second visit, during which informed consent was obtained and a posttest was administered.
RESULTS: As reflected by the percentage of correct answers on the pretest and posttest assessments, this model increased genetic knowledge by 11.1% (from 77.8% to 88.9%; P < .0001) in 121 parents participating in both the study introduction and consent visits. The percentage of parents correctly identifying the meaning of somatic and germline mutations increased significantly (from 18% to 59% [somatic] and from 31% to 64% [germline]; P < .0001). Nevertheless, these concepts remained unfamiliar to one-third of the parents. No relation was identified between the change in the overall percentage of correct answers and self-reported literacy, numeracy, or demographics.
CONCLUSIONS: The use of a 2-visit communication model improved knowledge of concepts relevant to genomic sequencing, particularly differences between somatic and germline testing; however, these areas remained confusing to many participants, and reinforcement may be necessary to achieve complete understanding.
© 2019 American Cancer Society.

Entities:  

Keywords:  bioethics; cancer predisposition; communication; genomic testing; informed consent; pediatric oncology

Year:  2019        PMID: 30901077     DOI: 10.1002/cncr.32071

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  Cancer predisposition in pediatric neuro-oncology-practical approaches and ethical considerations.

Authors:  Steffen Hirsch; Nicola Dikow; Stefan M Pfister; Kristian W Pajtler
Journal:  Neurooncol Pract       Date:  2021-05-28

2.  Factors Associated with Declining to Participate in a Pediatric Oncology Next Generation Sequencing Study.

Authors:  Katianne M Howard Sharp; Niki Jurbergs; Annastasia Ouma; Lynn Harrison; Elsie Gerhardt; Leslie Taylor; Kayla Hamilton; Rose B McGee; Regina Nuccio; Emily Quinn; Stacy Hines-Dowell; Chimene Kesserwan; Anusha Sunkara; Jami S Gattuso; Michelle Pritchard; Belinda Mandrell; Mary V Relling; Cyrine E Haidar; Guolian Kang; Liza M Johnson; Kim E Nichols
Journal:  JCO Precis Oncol       Date:  2020-03-24

3.  Creating a cancer genomics curriculum for pediatric hematology-oncology fellows: A national needs assessment.

Authors:  Alise K Murray; Rose B McGee; Roya M Mostafavi; Xiaoqing Wang; Zhaohua Lu; Jessica M Valdez; Michael A Terao; Kim E Nichols
Journal:  Cancer Med       Date:  2021-02-23       Impact factor: 4.452

Review 4.  Genomic Health Literacy Interventions in Pediatrics: Scoping Review.

Authors:  Aarushi Gupta; Joseph A Cafazzo; Maarten J IJzerman; Joost F Swart; Sebastiaan Vastert; Nico M Wulffraat; Susanne Benseler; Deborah Marshall; Rae Yeung; Marinka Twilt
Journal:  J Med Internet Res       Date:  2021-12-24       Impact factor: 5.428

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.